What Happened?
A number of stocks fell in the afternoon session after a key industry player warned that changes to some insurance plans could slow U.S. procedure growth, sparking fears of a sector-wide slowdown. The concern was raised by Intuitive Surgical, which noted that shifting insurance coverage could dampen the number of medical procedures performed in the United States.
This news has investors worried about near-term demand, not just for one company, but for the entire industry reliant on a steady volume of procedures. The warning suggests that even with strong individual company performance, broader healthcare policy and insurance plan adjustments can create significant headwinds.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.
Among others, the following stocks were impacted:
- Medical Devices & Supplies - Specialty company STAAR Surgical (NASDAQ:STAA) fell 10.1%. Is now the time to buy STAAR Surgical? Access our full analysis report here, it’s free.
- Medical Devices & Supplies - Specialty company Globus Medical (NYSE:GMED) fell 4.4%. Is now the time to buy Globus Medical? Access our full analysis report here, it’s free.
- Medical Devices & Supplies - Specialty company Integer Holdings (NYSE:ITGR) fell 4.1%. Is now the time to buy Integer Holdings? Access our full analysis report here, it’s free.
- Medical Devices & Supplies - Specialty company Enovis (NYSE:ENOV) fell 5.1%. Is now the time to buy Enovis? Access our full analysis report here, it’s free.
Zooming In On STAAR Surgical (STAA)
STAAR Surgical’s shares are very volatile and have had 28 moves greater than 5% over the last year. But moves this big are rare even for STAAR Surgical and indicate this news significantly impacted the market’s perception of the business.
The biggest move we wrote about over the last year was 12 months ago when the stock gained 45.6% on the news that eye-care company Alcon announced a definitive agreement to acquire the company in an all-cash deal valued at approximately $1.5 billion. Under the terms of the deal, Alcon paid $28 in cash for each share of STAAR Surgical.
This price marked a 51% premium to the company's closing stock price on the previous day. STAAR Surgical manufactured implantable lenses for vision correction, including its EVO family of Implantable Collamer® Lenses. The acquisition allowed Alcon to absorb a key player in the ophthalmic surgery space.
STAAR Surgical is up 11.4% since the beginning of the year, but at $26.28 per share, it is still trading 21.2% below its 52-week high of $33.34 from May 2026. Despite the year-to-date gain, investors who bought $1,000 worth of STAAR Surgical’s shares 5 years ago would now be looking at only $198.41.
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.